Marijuana does have anti-inflammatory properties, but the answer depends heavily on which compounds you’re talking about. CBD consistently reduces key inflammatory markers in research studies, while THC alone does not, and in some cases may increase inflammation. The plant also contains dozens of other compounds with anti-inflammatory activity, making the full picture more nuanced than a simple yes or no.
How Cannabis Interacts With Inflammation
Your body has a built-in system called the endocannabinoid system that helps regulate pain and immune responses. It uses two main receptors: CB1, found primarily in the brain and nervous system, and CB2, found widely on immune cells throughout the body. Your body naturally produces molecules that activate these receptors, but compounds in cannabis can activate them too.
CB2 receptors are the more relevant ones for inflammation. When activated, they suppress the release of pro-inflammatory signals from immune cells, dialing down the local inflammatory response. This happens both in surrounding tissue and in the central nervous system. CB1 receptors, meanwhile, are more involved in pain perception. They sit on nerve terminals in the spinal cord and brain, where they regulate how pain signals are transmitted by controlling the release of chemical messengers between neurons. So cannabis compounds can influence both the inflammation itself and how much pain that inflammation causes.
CBD Reduces Inflammation, THC Alone Does Not
A systematic review of animal studies found a clear split between the two most well-known cannabinoids. CBD consistently lowered levels of the major pro-inflammatory molecules: tumor necrosis factor alpha (a protein that drives swelling and tissue damage), interleukin-6, interleukin-1 beta, and interferon gamma. These are the same molecules that go haywire in conditions like rheumatoid arthritis and inflammatory bowel disease.
THC alone told a different story. Across three studies, it failed to reduce any of these inflammatory markers. In one study, THC actually increased levels of all three major pro-inflammatory molecules and caused tissue damage. A combination of CBD and THC did show anti-inflammatory effects, suggesting CBD may counterbalance THC’s inflammatory tendencies. Another lesser-known cannabinoid called CBG also reduced inflammation in the studies that tested it.
This distinction matters if you’re choosing a product specifically for inflammation. A THC-dominant strain may help with pain perception through its effects on CB1 receptors in the nervous system, but it’s not doing much to calm the underlying inflammatory process. CBD-dominant or balanced products have stronger evidence for actually reducing inflammation at the cellular level.
Terpenes Add to the Anti-Inflammatory Effect
Cannabis contains dozens of aromatic compounds called terpenes that contribute their own anti-inflammatory activity. The most notable is beta-caryophyllene, a spicy-smelling compound that is the only terpene known to directly bind to CB2 receptors on immune cells, essentially mimicking the anti-inflammatory action of cannabinoids through the same pathway. It also has pain-relieving and neuroprotective properties.
Myrcene, the most abundant terpene in most cannabis varieties, has anti-inflammatory, pain-relieving, and sedative effects. Alpha-pinene acts as both an anti-inflammatory and a bronchodilator. Alpha-humulene, gamma-terpinene, and guaiol all show anti-inflammatory activity as well. Research on terpene-rich hemp essential oils has confirmed that these compounds contribute meaningfully to the plant’s overall anti-inflammatory profile, which is why whole-plant products may work differently than isolated cannabinoids.
What the Clinical Evidence Shows
The gap between lab results and real-world clinical outcomes is where things get complicated. In Crohn’s disease, a meta-analysis of randomized controlled trials found that cannabis users had significantly higher clinical remission rates at eight weeks compared to placebo groups. However, the reduction in C-reactive protein (a blood marker of systemic inflammation) did not reach statistical significance. This suggests cannabis may be improving symptoms and overall disease activity without fully suppressing measurable inflammation in the blood.
In rheumatoid arthritis, results are mixed. One clinical trial using a pharmaceutical spray containing both THC and CBD found significant improvements in movement pain, resting pain, and sleep quality, but no improvement in morning stiffness. More concerning, a separate clinical study found that CBD oil actually increased the expansion of a type of immune cell linked to autoimmune inflammation, and disease activity scores worsened during the treatment period. This is a reminder that immune modulation is complex, and suppressing one inflammatory pathway can sometimes amplify another.
No cannabis product is currently FDA-approved for treating any inflammatory condition. The FDA has approved one cannabis-derived drug and three cannabis-related drugs, but none target inflammation specifically.
How You Take It Matters
The route of administration significantly affects how much of the active compounds actually reach your system. When you swallow CBD or THC, oral bioavailability can be as low as 6%, meaning the vast majority is broken down by your liver before it ever reaches your bloodstream. Even higher estimates put oral CBD bioavailability at only 13 to 19%. Intranasal absorption roughly doubles that to 34 to 46%, and rectal administration doubles it compared to oral.
For localized inflammation, like a sore joint or inflamed skin, topical application bypasses the digestive system entirely. Clinical studies have found that CBD-enriched topical ointments significantly improved skin conditions, and a pilot study showed that a topical cannabinoid emulsion resolved mild atopic dermatitis in 80% of patients while preventing relapse. Topical products deliver cannabinoids directly to the affected area without the systemic side effects of oral consumption, making them a practical option for surface-level inflammatory issues.
For deeper or systemic inflammation, topical application won’t be enough. Inhalation delivers cannabinoids to the bloodstream quickly but carries respiratory risks with long-term use. Oral products, despite their low bioavailability, provide longer-lasting effects. Clinical dosing guidelines for inflammatory pain typically start with 5 mg of CBD twice daily, increasing by 10 mg every two to three days up to 40 mg per day. If CBD alone isn’t sufficient, small amounts of THC (starting at 1 to 2.5 mg per day) may be added gradually.
Risks of Long-Term Use
Using cannabis chronically for inflammation management comes with its own set of health trade-offs. Cardiovascular risks are among the most serious: regular cannabis use is linked to increased rates of heart disease, irregular heart rhythms (including atrial fibrillation), and cardiomyopathy. The immediate effect of cannabis is a spike in heart rate and blood pressure, followed by a drop in both, and this cycle creates conditions for dangerous rhythm disturbances.
Inhaled cannabis, especially with the deep inhalation common among users, accelerates the decline in lung function and increases the risk of chronic obstructive pulmonary disease. Chronic use can also lead to cannabis hyperemesis syndrome, a condition involving cycles of severe nausea, vomiting, and abdominal pain that is increasingly common as cannabis use has expanded. Psychiatric risks include higher rates of anxiety, depression, and bipolar disorder among regular users, with high-potency products linked to a greater risk of psychotic disorders. THC carries addiction potential through its effects on reward pathways in the brain.
These risks are most relevant to people using THC-containing products over months or years. CBD-only products carry a milder side effect profile, though long-term data is still limited. The arthritis study where CBD worsened disease activity scores is a useful caution: anti-inflammatory effects in a lab dish don’t automatically translate to safe, effective treatment in a living body with a complex immune system.